| 摘要 |
PROBLEM TO BE SOLVED: To provide pharmaceutical formulations for pulmonary delivery having utility as pharmaceutical formulations for treating diseases such as diabetes, cancers, and obesity.SOLUTION: Provided are dry powder compositions for pulmonary administration containing microparticles of glucagon-like peptide 1 (GLP-1) in combination with pharmaceutically acceptable salts of diketopiperazine (DKP) that are stable both in vitro and in vivo. The pharmaceutically acceptable salts of diketopiperazine have the formula of 2,5-diketo-3,6-di(4-X-aminobutyl)piperazine, where X is selected from the group consisting of succinyl, glutaryl, maleyl, and fumaryl, and preferably are 2,5-diketo-3,6-di(4-fumaryl-aminobutyl)piperazine disodium salts. |
